Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

r>(unaudited; in thousands, except per share data)Three Months EndedSix Months EndedDec. 31,Sep. 30,Dec. 31,Dec. 31, Dec. 31,20122012201120122011GAAP net income$
41,927$
75,606$
56,253$
7,533$
41,715Adjustments:Research and Development share-based compensation (2)

2,7672,5901,7015,3573,239General and Administrative share-based compensation (2)

1,5035766752,0791,3014,2703,1662,3767,4364,540Non-GAAP net income$
46,197$
78,772$
58,629$
24,969$
46,255GAAP net income per share - basic$
.60$
.09$
.82$
.69$
.61Share-based compensation expense

0.060.040.030.100.07Non-GAAP net income per share - basic$
.66$
.13$
.85$
.79$
.68GAAP net income per share - diluted$
.56$
.02$
.78$
.580.58Share-based compensation expense

0.060.040.040.100.07Non-GAAP net income per share - diluted$
.62$
.06$
.82$
.68$
.65(1) This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our financial statements prepared in accordance with GAAP.(2) All share-based compensation was excluded for the non-GAAP analysis.
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... million which brings Q3 orders to $5.8 million and provides a ... projects in North America and one in ... to bid new projects at record levels," said Peter Bruijns ... higher at the end of Q3 than they have been for ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/20/2014)... October 20, 2014 Local veterinary surgeon, ... an investigational study of donor stem cells for dogs ... cell therapy and has performed clinical stem cell therapy ... is to determine if a single injection of donor ... can help reduce pain and inflammation in the treated ...
(Date:10/19/2014)... NextCODE Health, which enables clinicians and researchers to use full ... the launch of its new genomic data analysis and collaboration ... of Human Genetics (ASHG) annual meeting in San ... for free beta access, visit www.nextcode.com . A brief ... here . The Exchange: , ...
Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... February 25 Arpida Ltd,(SIX: ARPN) announced today its financial results for the ... - Setback in regulatory process for intravenous iclaprim in ... - Top-line results of "intravenous-to-oral" Phase II trial with ... - Leadership change, - Share placing, ...
... Cerimon Pharmaceuticals, Inc., announced today the Company has enrolled ... patch Phase III program. The program consists of ... Cerimon,s diclofenac patch. The studies will assess the ... placebo for the treatment of acute pain caused by ...
... Speid & Associates, an international regulatory and drug ... entered into a partnership with Genizon BioSciences to ... Genizon,s proprietary genetic platform. In this challenging ... companies have to watch every dollar that is ...
Cached Biology Technology:Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds 2
(Date:10/15/2014)... pneumonia in female mice to an enzyme activated by ... more resistant to respiratory infections than males. Now, an ... to bacterial pneumonia in female mice is linked to ... show that this enzyme is ultimately activated by the ... team, lead by Professor Lester Kobzik at the Harvard ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... fish oil supplements, rich in omega-3 fatty acids, do not ... which the heart can beat as fast as 150 beats ... the Montreal Heart Institute were published in the Journal ... , For the trial, 337 patients with atrial fibrillation not ... of fish oil a day or to placebo for up ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... more attractive to women seeking short-term relationships, scientists at ... previously assumed that in Western cultures scarring was an ... perceived as a sign of maturity and strength. ... that Western women find scarring on men attractive and ...
... the presidential campaign, Barack Obama proposed an economic plan ... These so-called "green collar" jobs do, in fact, present ... report from Duke University. , Highlighting the direct ... say U.S. manufacturing is poised to grow in a ...
... A new study confirms that exercise can reverse the ... in the hippocampus of the mouse brain, and suggests ... which promotes the production and maturation of new stem ... into a variety of mature nerve cells which have ...
Cached Biology News:Scientists find facial scars increase attractiveness 2Duke study pinpoints potential 'green collar' job growth in US 2Exercise increases brain growth factor and receptors, prevents stem cell drop in middle age 2Exercise increases brain growth factor and receptors, prevents stem cell drop in middle age 3
RABBIT ANTI PARATHION...
Similar to proteasome (prosome, macropain) 26S subunit, ATPase, 1 Antigen: Recombinant Protein...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
Biology Products: